Clinical Trial Detail

NCT ID NCT01897012
Title Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

Burkitt lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

mantle cell lymphoma

lymphoma

Hodgkin's lymphoma

Therapies

romidepsin

Alisertib

Age Groups: adult

Additional content available in CKB BOOST